Mechanistic and therapeutic insights into class A GPCR dimers in neuropsychiatric disorders Authors: Zhaojing Wang, Linlin Wang, Shicheng Zhang Published: 2026 ABSTRACT Class A G protein-coupled receptors (GPCRs) constitute the majority of the clinical GPCR targets and are implicated in a wide range of neuropsychiatric disorders. Dimerization of class A GPCRs often introduces unique modes of allosteric modulation, leading to the reprogramming of the downstream signaling relative to individual protomers. In this review, we highlight the experimental evidence and pharmacological properties of class A GPCR dimers involved in mental disorders. We further elucidate the molecular basis of dimer assembly and activation through a comprehensive structural analysis of currently available class A GPCR dimers. Current strategies and therapeutic potential of dimer-specific targeting are also discussed. Together, these insights provide a framework for understanding class A GPCR dimer function and pave the way for the development of dimer-informed therapeutics. Introduction G protein-coupled receptors (GPCRs) constitute the largest family of membrane proteins, with more than 800 members in the human genome. They transduce a wide range of extracellular signals into intracellular responses, thereby regulating diverse physiological and pathophysiological processes across various tissues and organs1. Notably, approximately 90% of GPCRs are predominantly expressed in the brain2, underscoring their pivotal role in regulating neural communication and behavior. Based on the sequence homology and evolutionary relationship, the GPCR superfamily is mainly divided into four classes: class A (rhodopsin), class B (B1: secretin and B2: adhesion), class C (glutamate), and class F (frizzled and smoothened)3 (Fig. 1a). Among these, class A GPCRs, also known as rhodopsin-like receptors, comprise the largest subgroup (719 members) and play crucial roles in human physiology4. Currently, more than 30% of FDA-approved drugs target GPCRs, the majority of which (130 out of 151) belong to the class A family5,6. Remarkably, all top ten GPCRs most frequently targeted by approved drugs belong to aminergic receptors, a subgroup in the class A family, including dopamine, serotonin, acetylcholine, adrenergic, and histamine receptors6, which play central roles in modulating brain functions and maintaining mental health.Fig. 1Classification and signaling pathways of GPCRs.a The structural features and activation hallmarks of class A, B1, B2, C, and F GPCRs. The inactive- and active-state structures are colored as pale green and light blue, respectively. The common activation hallmark of monomeric GPCRs is the outward movement of TM6. The dimeric class C GPCRs activation induced the TMs rearrangement, and the dimer interface converges to involve TM6. The superimposed structures from left to right are as follows: β2-adrenergic receptor (β2AR), inactive state (Protein Data Bank (PDB) ID: 2R4R), active state (PDB ID: 3SN6); parathyroid hormone (PTH) type 1 receptor (PTH1R), inactive state (PDB ID: 6FJ3), active state (PDB ID: 6NBF); adhesion G protein-coupled receptor E5 (ADGRE5/CD97), inactive state (PDB ID: 8IKJ), active state (PDB ID: 8IKL); metabotropic glutamate 2 (mGlu2) homodimer, inactive state (PDB ID: 7MTQ), active state (PDB ID: 7MTS); Smoothened (SMO), inactive state (PDB ID: 4N4W), active state (PDB ID: 6OT0). b Representation of different types of orthosteric ligands induced monomeric GPCR signaling. c Examples of pharmacological response curves for agonist, partial agonist, antagonist, and inverse agonist. d Examples of pharmacological response curves for arrestin-biased agonist. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. Classification and signaling pathways of GPCRs. a The structural features and activation hallmarks of class A, B1, B2, C, and F GPCRs. The inactive- and active-state structures are colored as pale green and light blue, respectively. The common activation hallmark of monomeric GPCRs is the outward movement of TM6. The dimeric class C GPCRs activation induced the TMs rearrangement, and the dimer interface converges to involve TM6. The superimposed structures from left to right are as follows: β2-adrenergic receptor (β2AR), inactive state (Protein Data Bank (PDB) ID: 2R4R), active state (PDB ID: 3SN6); parathyroid hormone (PTH) type 1 receptor (PTH1R), inactive state (PDB ID: 6FJ3), active state (PDB ID: 6NBF); adhesion G protein-coupled receptor E5 (ADGRE5/CD97), inactive state (PDB ID: 8IKJ), active state (PDB ID: 8IKL); metabotropic glutamate 2 (mGlu2) homodimer, inactive state (PDB ID: 7MTQ), active state (PDB ID: 7MTS); Smoothened (SMO), inactive state (PDB ID: 4N4W), active state (PDB ID: 6OT0). b Representation of different types of orthosteric ligands induced monomeric GPCR signaling. c Examples of pharmacological response curves for agonist, partial agonist, antagonist, and inverse agonist. d Examples of pharmacological response curves for arrestin-biased agonist. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. From a pharmacological perspective, GPCR ligands are broadly classified according to their functional efficacy as full agonists, partial agonists, antagonists, and inverse agonists (Fig. 1b, c). The conformational plasticity of GPCRs allows them to adopt multiple states, such as active, inactive, and signaling-biased states, each associated with distinct downstream outcomes1. In addition to the monomeric signaling, GPCRs can form functional dimers or higher-order oligomers, adding another layer of regulation to receptor pharmacology. In contrast to the clear understanding of class C GPCR dimerization7, there is still no consensus on the physiological role of class A GPCR dimerization8,9. This uncertainty largely arises from the transient nature of class A GPCR dimers and technical limitations in capturing their dynamic assemblies under physiological conditions. Nevertheless, studies of specific receptor pairs, such as the heterodimer of dopamine receptors D1R-D2R10–16, serotonin receptors 5-HT1AR-5-HT2AR17,18, and cannabinoid receptors CB1R-CB2R19, have provided compelling evidence that class A GPCR dimerization plays a critical role in shaping neurotransmission and behavioral regulation (Table 1).Table 1Class A GPCR dimers and potential roles in neuropsychiatric disordersReceptor 1Receptor 2Clinical RelevanceMethodsSignaling/Functional evidenceReferenceIn vitroIn vivoD1RD2RDrug addiction, schizophrenia, depressionCo-IP, confocal FRETCo-IP, confocal FRET, IHCSwitched signaling, dissociation, increased agonist affinity10–16D1RD3RPD, schizophreniaFRET, BRET, CODA-RETCo-IPIncreased agonist affinity, biased signaling, positive/negative crosstalk47–51D2RD3RSchizophrenia, PD, ADHDCo-IP, RT-FRETPositive/negative crosstalk32,52–55D2RD4RADHDBRET, PLAPositive crosstalk56,57D2RD5RDrug addiction, schizophreniaFRETIHCNegative crosstalk96,97D1RA1RDrug addiction, PDCo-IP, BRET, BiFCCo-IP, PLANegative crosstalk, biased signaling67–69D2RA2ARDrug addiction, schizophrenia, PDCo-IP, FRET, BRET, BiFCCo-IP, PLANegative crosstalk, decreased agonist/antagonist affinity70–75D3RA2ARSchizophreniaFRET, IHCNegative crosstalk, decreased agonist affinity76D1RH3RDrug addictionBRETCo-IP, IHC, PLANegative crosstalk58–60D2RH3RDepression, drug addiction, schizophrenia, PDBRETNegative crosstalk, decreased agonist affinity65D1RMORDrug addictionBRET, Co-IPCo-IPCross inhibition80D2RMORDrug addictionBRET, NanoBiT, FRET, Co-IPNegative crosstalk81D2RNTSR1Schizophrenia, PDBRET, PLACo-IP, IHCNegative crosstalk82–84,105D3RNTSR1Schizophrenia, PDBRETBiased signaling85D2RSSTR5DepressionFRETPLAAssociation86,87D2RTAAR1SchizophreniaBRETPositive crosstalk, dissociation66D2ROTRAnxiety, PD, ASDBRET, PLACo-IP, PLAPositive crosstalk, increased agonist affinity88–905-HT1AR5-HT2ARDepression, schizophreniaBRETPLADecreased agonist affinity, formation17,185-HT1AR5-HT7RDepression, anxietyFRETCo-IPBiased signaling108,1095-HT2AR5-HT2CRSchizophrenia, depressionCo-IP, BRETNegative crosstalk, decreased agonist affinity1105-HT2BR5-HT2CRSchizophrenia, depressionCo-IP, BRETNegative crosstalk, decreased agonist affinity1105-HT1ARD2RSchizophreniaFRETPLAPositive crosstalk, formation, dissociation18,615-HT2ARD2RSchizophreniaCo-IP, PLA, BRETPositive crosstalk, negative crosstalk, increased agonist affinity62–645-HT2AROTRSchizophrenia, ASDFRETPLANegative crosstalk1115-HT2CROTRSchizophrenia, ASDFRETPLANegative crosstalk, biased signaling1125-HT1ARGalR1DepressionPLA, FRETNegative crosstalk1135-HT1ARMORDrug addiction, depressionCo-IP, BRETCross activation1145-HT2CRMT2RDepression, anxietyCo-IP, BRETCross activation, unbalanced signaling116,117CB1RCB2RAD, PDBRET, IHCPLANegative crosstalk, cross inhibition19CB1RD2RHuntington’s diseaseCo-IP, IHC, BRET, SRET, BiFCSwitched signaling, biased signaling, formation77–79CB1R5-HT2ARSchizophrenia, ADBRET, BiFC, PLANegative crosstalk, cross inhibition, switched signaling, formation45,115GalR1GalR2DepressionBRETPLABiased signaling133 Table 1Class A GPCR dimers and potential roles in neuropsychiatric disordersReceptor 1Receptor 2Clinical RelevanceMethodsSignaling/Functional evidenceReferenceIn vitroIn vivoD1RD2RDrug addiction, schizophrenia, depressionCo-IP, confocal FRETCo-IP, confocal FRET, IHCSwitched signaling, dissociation, increased agonist affinity10–16D1RD3RPD, schizophreniaFRET, BRET, CODA-RETCo-IPIncreased agonist affinity, biased signaling, positive/negative crosstalk47–51D2RD3RSchizophrenia, PD, ADHDCo-IP, RT-FRETPositive/negative crosstalk32,52–55D2RD4RADHDBRET, PLAPositive crosstalk56,57D2RD5RDrug addiction, schizophreniaFRETIHCNegative crosstalk96,97D1RA1RDrug addiction, PDCo-IP, BRET, BiFCCo-IP, PLANegative crosstalk, biased signaling67–69D2RA2ARDrug addiction, schizophrenia, PDCo-IP, FRET, BRET, BiFCCo-IP, PLANegative crosstalk, decreased agonist/antagonist affinity70–75D3RA2ARSchizophreniaFRET, IHCNegative crosstalk, decreased agonist affinity76D1RH3RDrug addictionBRETCo-IP, IHC, PLANegative crosstalk58–60D2RH3RDepression, drug addiction, schizophrenia, PDBRETNegative crosstalk, decreased agonist affinity65D1RMORDrug addictionBRET, Co-IPCo-IPCross inhibition80D2RMORDrug addictionBRET, NanoBiT, FRET, Co-IPNegative crosstalk81D2RNTSR1Schizophrenia, PDBRET, PLACo-IP, IHCNegative crosstalk82–84,105D3RNTSR1Schizophrenia, PDBRETBiased signaling85D2RSSTR5DepressionFRETPLAAssociation86,87D2RTAAR1SchizophreniaBRETPositive crosstalk, dissociation66D2ROTRAnxiety, PD, ASDBRET, PLACo-IP, PLAPositive crosstalk, increased agonist affinity88–905-HT1AR5-HT2ARDepression, schizophreniaBRETPLADecreased agonist affinity, formation17,185-HT1AR5-HT7RDepression, anxietyFRETCo-IPBiased signaling108,1095-HT2AR5-HT2CRSchizophrenia, depressionCo-IP, BRETNegative crosstalk, decreased agonist affinity1105-HT2BR5-HT2CRSchizophrenia, depressionCo-IP, BRETNegative crosstalk, decreased agonist affinity1105-HT1ARD2RSchizophreniaFRETPLAPositive crosstalk, formation, dissociation18,615-HT2ARD2RSchizophreniaCo-IP, PLA, BRETPositive crosstalk, negative crosstalk, increased agonist affinity62–645-HT2AROTRSchizophrenia, ASDFRETPLANegative crosstalk1115-HT2CROTRSchizophrenia, ASDFRETPLANegative crosstalk, biased signaling1125-HT1ARGalR1DepressionPLA, FRETNegative crosstalk1135-HT1ARMORDrug addiction, depressionCo-IP, BRETCross activation1145-HT2CRMT2RDepression, anxietyCo-IP, BRETCross activation, unbalanced signaling116,117CB1RCB2RAD, PDBRET, IHCPLANegative crosstalk, cross inhibition19CB1RD2RHuntington’s diseaseCo-IP, IHC, BRET, SRET, BiFCSwitched signaling, biased signaling, formation77–79CB1R5-HT2ARSchizophrenia, ADBRET, BiFC, PLANegative crosstalk, cross inhibition, switched signaling, formation45,115GalR1GalR2DepressionBRETPLABiased signaling133 Class A GPCR dimers and potential roles in neuropsychiatric disorders Although accumulating evidence suggests that class A GPCR dimerization regulates downstream signaling pathways and participates in physiological or pathological processes, mechanistic insight remains limited. Notably, many dimers exhibit pharmacological and signaling behaviors that differ from monomeric receptors, as inter-protomer allosteric modulation can cause the same ligand to produce distinct signaling outputs in monomers versus dimers20–22. These unique properties of dimerization highlight the potential of dimer-specific targeting to open new therapeutic opportunities in neuropsychiatric disorders. In this review, we integrate current pharmacological and structural findings on class A GPCR dimers, with specific emphasis on their modes of assembly, signaling properties, and activation mechanisms. By consolidating these advances, we aim to provide a more systematic understanding of class A GPCR dimerization paradigms and establish a conceptual framework to guide the development of dimer-targeted therapeutic strategies for neuropsychiatric disorders. Class A GPCR dimers in neuropsychiatric disorders Class A GPCRs, which are abundantly expressed in the brain, play essential roles in regulating mood, cognition, and behavior, thereby contributing significantly to the pathophysiology of neuropsychiatric disorders22,23. In addition to their monomeric signaling properties, the functional roles of class A GPCR dimers have also been increasingly explored8,9 (Table 1). Compared with homodimers, heterodimers display greater functional diversity and allosteric modulation, which often results in distinct pharmacological and pathological profiles. Consequently, growing evidence highlights the critical involvement of class A GPCR heterodimers in neuropsychiatric disorders and their status as promising targets for therapeutic intervention22,23. To establish the physiological existence of a heterodimer, at least two of the following criteria should be satisfied24: (1) the constituent protomers are colocalized within the same cellular compartment; (2) direct physical interaction between receptor pairs is experimentally verified in native tissue; (3) the heterodimer exhibits distinct pharmacological properties compared with its monomeric counterparts; (4) the elimination of either protomer results in the complete loss of specific signal transduction mediated by the heterodimeric complex. In this section, we summarize both the experimental approaches used to detect GPCR dimerization and the class A GPCR heterodimers that meet the criteria described above and are implicated in neuropsychiatric disorders, with a focus on their distinctive allosteric protomer interactions and associated changes in ligand properties and signaling outcomes (Table 1). Detecting GPCR dimer and decoding allostery The existence of GPCR dimers in native membrane environments requires validation through multiple complementary techniques to achieve definitive evidence. A variety of biochemical and biophysical methods have been developed to characterize the GPCR dimerization (Table 2 and Fig. 2). Commonly used biochemical approaches include co-immunoprecipitation (Co-IP), immunohistochemistry (IHC), and proximity ligation assay (PLA)25. While methods like IHC can reveal co-localization of receptors at endogenous levels and PLA can visualize dimeric interactions directly under physiological conditions, they also suffer from limitations, including high antibody dependence and limited spatial resolution, which may lead to false-positive results. More importantly, biochemical approaches are generally unsuitable for investigating dimeric interactions in living cells, thereby preventing real-time observation of GPCR dimer formation and the dynamics of associated signaling events26.Fig. 2Schematic representation of complementation- and RET-based approaches for GPCR dimer detection in living cells.a BiFC/BiLC. Once the split fragments-tagged receptor forms a dimer, the split fragments would reconstitute a functional unit and luminescence emission in the presence of λex or a substrate. On the right, examples of luminescence response curves for GPCR monomer or dimer with increasing ratio of spilt fragment 1 to spilt fragment 2 and ligand-induced dynamic dimer formation process. b FRET/BRET. When the distance between donor- and acceptor-tagged receptors is in proximity ( < 100 Å), resonance energy would transfer from a fluorophore donor or a bioluminescent donor to a nearby acceptor in the presence of excitation light (λex) or a substrate. On the right, examples of RET ratio response curves for GPCR monomer or dimer in the RET competition and RET saturation assays. c CODA-RET. Based on the BiLC and BRET with split fragments-tagged receptor and acceptor-tagged transducers (miniG or arrestin). The luminescence emission reflects the dimer formation, and the RET response represents the transducer recruitment. On the right, examples of donor luminescence response curve for the dynamic dimer formation process and RET ratio response curve for GPCR monomer or dimer recruitment. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu.Table 2Methods for probing GPCR dimer dimerizationMethodPrincipleIn vivo/in vitroKey advantagesKey disadvantagesCo-IPBiochemistryIn vivo/in vitroa. In the complex physiological environmentb. Under the endogenous expression levela. Unsuitable for dynamic dimer formation and signaling in living cellsb. High antibody dependencyc. False-positive resultsIHCPLABiFC/BiLCBiophysicsIn vitroa. Studying dimeric interactions in living cells.b. Detecting dynamic dimer formationa. Unsuitable for in vivo studyb. Need tagged-receptor /transducer overexpressionFRET/BRETa. Studying dimeric interactions in living cells.TR-FRETa. Studying dimeric interactions in living cells.b. High sensitivity: increased the assay window and reduced the backgroundsmFRETa. Studying dimeric interactions in living cells.b. Spatiotemporally transient detectionCODA-RETa. Studying precise dimeric interactions exclude unfavorable receptor complex in living cells.b. Detecting dynamic signal protein recruitmentc. Detecting dynamic dimer formation Schematic representation of complementation- and RET-based approaches for GPCR dimer detection in living cells. a BiFC/BiLC. Once the split fragments-tagged receptor forms a dimer, the split fragments would reconstitute a functional unit and luminescence emission in the presence of λex or a substrate. On the right, examples of luminescence response curves for GPCR monomer or dimer with increasing ratio of spilt fragment 1 to spilt fragment 2 and ligand-induced dynamic dimer formation process. b FRET/BRET. When the distance between donor- and acceptor-tagged receptors is in proximity ( < 100 Å), resonance energy would transfer from a fluorophore donor or a bioluminescent donor to a nearby acceptor in the presence of excitation light (λex) or a substrate. On the right, examples of RET ratio response curves for GPCR monomer or dimer in the RET competition and RET saturation assays. c CODA-RET. Based on the BiLC and BRET with split fragments-tagged receptor and acceptor-tagged transducers (miniG or arrestin). The luminescence emission reflects the dimer formation, and the RET response represents the transducer recruitment. On the right, examples of donor luminescence response curve for the dynamic dimer formation process and RET ratio response curve for GPCR monomer or dimer recruitment. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. Table 2Methods for probing GPCR dimer dimerizationMethodPrincipleIn vivo/in vitroKey advantagesKey disadvantagesCo-IPBiochemistryIn vivo/in vitroa. In the complex physiological environmentb. Under the endogenous expression levela. Unsuitable for dynamic dimer formation and signaling in living cellsb. High antibody dependencyc. False-positive resultsIHCPLABiFC/BiLCBiophysicsIn vitroa. Studying dimeric interactions in living cells.b. Detecting dynamic dimer formationa. Unsuitable for in vivo studyb. Need tagged-receptor /transducer overexpressionFRET/BRETa. Studying dimeric interactions in living cells.TR-FRETa. Studying dimeric interactions in living cells.b. High sensitivity: increased the assay window and reduced the backgroundsmFRETa. Studying dimeric interactions in living cells.b. Spatiotemporally transient detectionCODA-RETa. Studying precise dimeric interactions exclude unfavorable receptor complex in living cells.b. Detecting dynamic signal protein recruitmentc. Detecting dynamic dimer formation Methods for probing GPCR dimer dimerization a. In the complex physiological environment b. Under the endogenous expression level a. Unsuitable for dynamic dimer formation and signaling in living cells b. High antibody dependency c. False-positive results a. Studying dimeric interactions in living cells. b. Detecting dynamic dimer formation a. Unsuitable for in vivo study b. Need tagged-receptor /transducer overexpression a. Studying dimeric interactions in living cells. b. High sensitivity: increased the assay window and reduced the background a. Studying dimeric interactions in living cells. b. Spatiotemporally transient detection a. Studying precise dimeric interactions exclude unfavorable receptor complex in living cells. b. Detecting dynamic signal protein recruitment c. Detecting dynamic dimer formation In contrast, biophysical methods allow quantitative monitoring of GPCR dimerization dynamics in living cells, providing real-time insights into receptor assembly and associated signaling events. The bimolecular fluorescence or luminescence complementation (BiFC/BiLC), a classic method for detecting protein-protein interactions, has also been applied to investigate GPCR dimerization in the cellular systems25,26. These assays rely on the reconstitution of split fluorescent or luminescent proteins, where complementation restores a signal that is detected either through excitation (for fluorescence) or substrate addition (for luminescence)27, allowing visualization of dimer formation or dissociation in living cells (Fig. 2a). A major advance in studying GPCR dimerization has come from resonance energy transfer (RET)-based techniques, which provide high sensitivity and quantitative measurement of receptor proximity. RET occurs when donor- and acceptor-tagged receptors are within 100 Å, providing strong evidence for direct receptor interactions28,29. Depending on the excitation source, RET-based assays are primarily classified into fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) (Fig. 2b). These approaches allow real-time monitoring of GPCR dimerization kinetics using competition or saturation assays29 (Fig. 2b). In competition assays, untagged receptors compete with tagged ones, reducing RET signal, whereas saturation assays measure increasing RET as acceptor concentration rises until maximal energy transfer is reached30,31. Refinements such as time-resolved FRET (TR-FRET) use lanthanide donors to reduce autofluorescence and enhance detection sensitivity32,33. Single-molecule FRET (smFRET), particularly when combined with total internal reflection fluorescence (TIRF) microscopy, enables nanometer-scale imaging of individual GPCRs34. This approach provides precise spatial and temporal characterization of transient interactions, conformational changes, and dimer association or dissociation following ligand stimulation35,36. To detect and monitor signaling events that arise specifically from dimeric class A GPCRs, the complemented donor-acceptor resonance energy transfer (CODA-RET) assay was developed by integrating protein complementation with RET-based detection37 (Fig. 2c). This hybrid technique requires both physical proximity and energy transfer for signal generation, thereby enabling precise analysis of dimeric GPCR complexes. CODA-RET strictly defines which receptors participate in the energy transfer, allowing selective measurement of communication between specific receptor protomers and chosen signaling proteins while excluding homomeric complexes25,37,38. Moreover, CODA-RET can simultaneously capture ligand-induced dimer formation by monitoring luminescence from complemented receptor fragments alongside RET responses reflecting dimer recruitment dynamics (Fig. 2c). Alternatively, synthetic peptides mimicking TM domains can be used to evaluate the functional role of the dimeric GPCRs at endogenous levels in vivo or in vitro39. These exogenous synthetic TM peptides disrupt GPCR dimerization by blocking receptor-receptor assembly at the interface level40,41. Functionally, they serve as direct mechanistic probes. In vitro, they can serve as monomer-dimer conversion modulators in the aforementioned biophysical assays to quantify their effects on GPCR dimer dynamic formation process or downstream recruitment42. In vivo, they can be microinjected into specific brain regions to assess the functional and phenotypic consequences of dimer disruptio43,44. Moreover, peptide-induced reductions on the density of endogenous complexes in native tissues could be further visualized and quantified using PLA43,45. Consequently, synthetic TM peptides provide a powerful mechanistic approach for probing the physiological roles of GPCR dimerization, while helping to distinguish physiological receptor complexes from artifacts arising in overexpression-based systems. Dopamine receptor The dopamine receptor family is well involved in the dopaminergic signaling regulation, which is closely associated with numerous neuropsychiatric disorders46. The dopamine receptor family comprises five subtypes categorized into two subclasses: the D1R-like (D1R and D5R) and the D2R-like (D2R, D3R, and D4R) receptors, which couple to the Gs and Gi/o proteins, respectively. Recent studies have identified numerous dopamine receptor heterodimers that initiate signaling cascades distinct from those of monomeric receptors21. Reported heterodimers include: intra-DR family (D1R-D2R10–16, D1R-D3R47–51, D2R-D3R32,52–55, D2R-D4R56,57, and D2R-D5R56,57); with other aminergic receptors (D1R-H3R58–60, D2R-5-HT1AR18,61, D2R-5-HT2AR62–64, D2R-H3R65, and D2R-TAAR166); with adenosine and cannabinoid receptors (D1R-A1R67–69, D2R-A2AR70–75, D3R-A2AR76, and D2R-CB1R77–79); with neuropeptide receptors, including opioid (D1R-μOR80, D2R-μOR81), neurotensin (D2R-NTSR182–84, D3R-NTSR185), somatostatin (D2R-SSTR586,87), and oxytocin (D2R-OTR88–90) receptors (Table 1). However, the precise roles of dopamine receptor heterodimers in neuropsychiatric disorders remain to be fully elucidated. Most existing studies have focused on in vitro comparisons between dimeric and monomeric receptor functions, without direct evidence from relevant disease models. Nevertheless, insights into dimer-induced alterations in downstream signaling still provide a valuable basis for exploring their potential therapeutic significance. The D1R-D2R heterodimer dynamically interconverts with its monomeric subunit, with its expression enhanced in depression but decreased in schizophrenia13,91,92. Chronic amphetamine exposure upregulates the sensitivity and functional activity of this complex in the rat striatum, suggesting its involvement in conditions associated with hyperdopaminergic transmission12. Similarly, repeated cocaine administration elevates D1R-D2R heterodimer levels, further implicating it in addiction-related pathophysiology16. Consequently, D1R-D2R heterodimer was regarded as a promising pharmacological target for antipsychotic therapy with potentially fewer side effects93. A separate study reported that colocalization of D1R and D2R could not be detected in the adult brains of WT mice, rats, or monkeys under normal physiological conditions94. However, as discussed in a review article, this discrepancy likely reflects methodological limitations, given that the PLA probes used may have recognized nonspecific nuclear targets or been trapped in nuclei, thereby failing to detect cell surface expressed D1R and D2R22. Similarly, the physiological relevance of the D1R-D3R heterodimer remains controversial. Early studies reported that the activation of D3R could enhance the affinity of dopamine for the D1R and D1R-mediated responses in neurons47,48. However, the later findings showed that coactivation of both D1R and D3R led to the canonical negative interaction at the level of adenylyl cyclase (AC) signaling49 and a strong recruitment of β-arrestin1 (βarr1) and an increasing level of mitogen-activated protein kinase (MAPK) signaling49,51. This complex has also been implicated in L-DOPA-induced dyskinesia in PD and schizophrenia49,50. The D2R-D3R heterodimer represents another well-characterized example, exhibiting heightened response to D3R-preferential antiparkinsonian drugs, such as pramipexole and ropinirole, compared with monomeric receptors53,55. Interestingly, aripiprazole, a partial agonist of D2R, exhibits antagonist-like activity at this heterodimer54. Furthermore, the D2R-D4R heterodimer has been proposed to modulate corticostriatal glutamate transmission, and its dysfunction may contribute to ADHD pathophysiology57,95. Finally, the D2R-D5R heterodimer activated a calcium signal like D1R-D2R heterodimer96, with inactive D2R suppressing this response97, suggesting a potential involvement in drug addiction and schizophrenia98. The existence of a functional dopamine heterodimer with other aminergic receptors has also been revealed (Table 1). The histamine H3 receptor (H3R), highly expressed in the striatum, forms heteromers with the D1R58,59 and D2R65 and mediates negative modulations in both heterodimers, which may emerge and play a role in disorders involving the cortico-striatal-thalamo-cortical circuits, such as depression, schizophrenia, PD, and drug addiction59,65. In addition, D2R can heterodimerize with the trace amine-associated receptor 1 (TAAR1), as demonstrated by BRET66. Functional assays indicate that D2R antagonists selectively enhance TAAR1-mediated β-phenylethylamine (β-PEA)-induced cyclic adenosine monophosphate (cAMP) signaling, suggesting that the D2R-TAAR1 interaction could offer therapeutic opportunities for dopamine-related disorders, including schizophrenia66,99. The dopamine-serotonin heterodimers will be discussed in the subsequent section. Dopamine receptors further interact with adenosine and cannabinoid receptors, which would modulate dopaminergic tone (Table 1). The D1R-A1R heterodimer exhibits antagonistic modulation in spinal motoneurons67,68 and could be implicated in motor-aging disorders, including PD68,100. Repeated cocaine exposure reduces the level of functional A1R in the plasma membrane, which consequently leads to a decrease in the formation of the D1R-A1R heteromeric complex, highlighting relevance to addiction69. The D2R-A2AR and D3R-A2AR heterodimers also display reciprocal negative interactions: both A2AR agonists and antagonists decrease the affinity and intrinsic efficacy of D2-like receptor agonists, suggesting potential therapeutic applications for D2-like receptor-mediated disorders such as PD, schizophrenia, and addiction70,71,73,74,76,101. Similarly, the D2R-CB1R heterodimer shows allosteric interactions that modulate dopaminergic signaling77–79, potentially benefiting CNS disorders with disrupted dopaminergic or endocannabinoid signaling, such as Huntington’s disease102,103. Finally, dopamine receptors form heterodimers with neuropeptide GPCRs, including opioid (OR), neurotensin (NTSR), somatostatin (SSTR), and oxytocin (OTR) receptors (Table 1). The D1R-μOR80 and D2R-μOR81 heterodimers modulate the μOR agonist-induced signaling and receptor internalization, potentially reducing opioid side effects80,81,104. The D2R-NTSR1 and D3R-NTSR1 heterodimers could respond to the bivalent compounds and then mediate the β-arrestin recruitment and receptor internalization of D2-like receptors, implicating them in schizophrenia and neurodegenerative disorders such as PD85,105,106. The D2R-SSTR5 heterodimer exhibits ligand-dependent formation enhanced by antidepressant treatment86,87, while the D2R-OTR heterodimer facilitates oxytocin modulation of social and emotional behaviors, representing potential targets for anxiety, PD, and autism spectrum disorders88–90. Collectively, these heterodimers illustrate the extensive functional network of dopamine receptors and highlight multiple opportunities for pharmacological intervention in neuropsychiatric disorders. Serotonin receptor The monoamine neurotransmitter serotonin (5-Hydroxytryptamine, 5-HT) exerts its biological functions through the serotonin receptor (5-HTR) family. There are seven distinct types of 5-HTRs, including the ionotropic 5-HT3R and six metabotropic subfamilies: 5-HT1R, 5-HT2R, 5-HT4R, 5-HT5R, 5-HT6R, and 5-HT7R. These GPCR subfamilies display distinct G protein coupling preferences: 5-HT1Rs and 5-HT5R couple to Gi/o, 5-HT2Rs couple to Gq/11, and 5-HT4R, 5-HT6R, and 5-HT7R couple to Gs107. Numbers of functional 5-HTR heterodimers have been demonstrated through biochemical and biophysical approaches, including intra-5-HTR family (5-HT1AR-5-HT2AR17,18, 5-HT1AR-5-HT7R108,109, 5-HT2AR-5-HT2CR110, and 5-HT2BR-5-HT2CR110); with the dopamine receptor (5-HT1AR-D2R18,61 and 5-HT2AR-D2R62–64); with neuropeptide receptors including the oxytocin receptor (5-HT2AR-OTR111 and 5-HT2cR-OTR112), galanin receptor (5-HT1AR-GalR1113), and opioid receptor (5-HT1AR-μOR114); with other neuromodulatory receptors, such as cannabinoid receptor (5-HT2AR-CB1R45,115) and melatonin receptor (5-HT2cR-MT2R116,117) (Table 1). Given that 5-HTRs regulate numerous central and peripheral biological processes, their dysregulation has been implicated in psychiatric and neurological disorders, including depression, anxiety, schizophrenia, and drug addiction118,119. The identification of these functional heterodimers provides novel insight into 5-HTR-mediated signal integration in health and disease. Within the 5-HTR family, intra-receptor heterodimerization represents an important mechanism for fine-tuning serotonergic signaling. The 5-HT1AR-5-HT2AR heterodimer, visualized by PLA in the depression17 and ketamine-induced cognitive deficit models18, represents a potential target for depression and schizophrenia17,18. The 5-HT1AR-5-HT7R heterodimer preferentially couples to the 5-HT7R-mediated Gs signaling108 and is abundantly expressed on both presynaptic serotonergic and postsynaptic neurons, suggesting relevance to mood and anxiety disorders109. Among 5-HT2Rs, the 5-HT2AR-5-HT2CR and 5-HT2BR-5-HT2CR heterodimers exhibit altered Gq/11 coupling efficiency dominated by 5-HT2CR, a mechanism that may contribute to excitatory neurotransmission balance and the pathophysiology of depression and schizophrenia110,120. Cross-talk between serotonergic and dopaminergic systems is fundamental to neuropsychiatric function121,122. The 5-HT1AR-D2R heterodimer shows ligand-dependent dynamics: atypical antipsychotics such as clozapine, olanzapine, aripiprazole, and lurasidone enhance its formation61, whereas haloperidol decreases it18. Meanwhile, simultaneous treatment with clozapine (a weak D2R antagonist) and 8-OH-DPAT (a 5-HT1AR agonist) potentiates Gi/o signaling61. The 5-HT2AR-D2R heterodimer has been demonstrated in discrete regions of the ventral and dorsal striatum using in situ PLA64, while the physiological effects of the 5-HT2AR-D2R heterodimer remain inconsistent. Co-activation enhances 5-HT2AR-mediated Gq/11 signaling and intracellular calcium, while concurrently suppressing D2R-dependent Gi/o signaling62. Moreover, D2R activation enhances the binding affinity of hallucinogenic agonists (LSD and DOI) at 5-HT2AR and attenuates 5-HT2AR-mediated inositol phosphate production63, whereas LSD and DOI potentiate D2R agonist affinity and signaling64. The unique signaling profiles of 5-HT1AR-D2R and 5-HT2AR-D2R heterodimers position them as compelling therapeutic targets for schizophrenia through their modulation of dopaminergic and serotonergic neurotransmission61. Beyond dopaminergic systems, 5-HTRs also form heterodimers with several neuropeptide receptors, establishing further layers of cross-modulation. The 5-HT2AR/5-HT2CR-OTR heterodimers, coexpressed in regions controlling social cognition and emotional behaviors123,124, exhibit bidirectional antagonism that suppresses Gq/11 signaling in both protomers111,112, implicating them in social and affective regulation and as therapeutic targets for schizophrenia and autism spectrum disorder111. The 5-HT1AR-GalR1 heterodimer, coupling via Gi/o, shows allosteric inhibition that prevents excessive AC inhibition and MAPK activation113, suggesting an adaptive mechanism for stress control and antidepressant potential113,125. Similarly, the 5-HT1AR-μOR heterodimer displays μ-opioid agonist-induced cross-activation and antagonist-induced inhibition, while prolonged 5-HT1AR stimulation desensitizes μOR-induced ERK1/2 phosphorylation114,126. These interactions highlight cooperative mechanisms underlying analgesic, antidepressant, and anti-addictive effects114,126. Serotonergic heterodimers with other neuromodulatory GPCRs further extend serotonergic functional diversity (Table 1). The 5-HT2AR-CB1R heterodimer, coexpressed in the amygdala, cerebral cortex, and hippocampus127,128, exhibits cross-inhibition, simultaneous activation suppresses signaling from both receptors, and antagonist binding to one protomer inhibits the other45,115. This bidirectional control may underlie its relevance to cognitive and emotional dysfunctions such as schizophrenia and Alzheimer’s disease (AD)45,115. Similarly, the 5-HT2CR-MT2R heterodimer bridges the serotonergic and melatoninergic signaling. Functional studies show cross-activation within the heterodimer: melatonin activates both Gi/o signaling via MT2R and Gq/11 signaling through 5-HT2CR, whereas 5-HT stimulation does not induce reciprocal activation of MT2R116,117. This allosteric modulation illustrates a functional link between serotonergic and melatoninergic systems, offering therapeutic implications for major depressive and anxiety disorders and potential for chronotherapeutic interventions116,117. Taken together, these functional heterodimers regulate serotonergic neurotransmission in a manner distinct from monomeric serotonin receptors, thereby providing novel insights in both physiological and pathological contexts. Other class A receptors In addition to dopamine- and serotonin-centered heterodimers, other Class A GPCRs, such as cannabinoid and galanin receptors, also form functionally relevant heteromeric complexes (Table 1). Both CB1R and CB2R transduce signals via the Gi/o pathway129. CB1R is abundantly expressed in the CNS, whereas CB2R, though expressed at much lower levels, is detected in hippocampal CA1 neurons, suggesting a critical role in cognitive regulation130. The dynamic changes in CB1R-CB2R heterodimer expression have been revealed during disease progression19. Specifically, upregulation of CB1R-CB2R heterodimer was observed in activated microglia, with prominent increases noted in the hippocampal microglia of the AD model and the striatal microglia of the PD model131. Functionally, coactivation of CB1R (selective agonist: Arachidonyl-2-chloroethylamide, ACEA) and CB2R (selective agonist: JWH 133) resulted in a negative crosstalk in Akt/PKB phosphorylation and neurite outgrowth19. Moreover, bidirectional cross-inhibition occurs within the complex, as antagonists of either receptor can block agonist-induced signaling of its partner19. These findings suggest that the CB1R-CB2R heterodimer in activated microglia may serve as a potential therapeutic target for neurodegenerative diseases such as AD and PD. Similarly, galanin receptors form heterodimers that fine-tune signaling specificity and contribute to neuropsychiatric pathophysiology. GalR1 and GalR2 couple to Gi/o and Gq/11 pathways, respectively, and are implicated in pain control as well as the modulation of depression and AD132. The GalR1-GalR2 heterodimer has been detected in the hippocampal formation and midbrain raphe nuclei of rats133. Functionally, the galanin fragment (1–15) selectively activates GalR1-mediated Gi/o signaling while failing to engage GalR2-mediated Gq/11 signaling, a mechanism potentially linked to depressive pathophysiology133. Dynamic and allosteric modulation of class A GPCR dimerization Class A GPCR dimers often exhibit distinct functional properties compared to their monomeric counterparts, suggesting stimulus-induced conformational changes in one protomer could allosterically modulate the function of the other134. Elucidating the molecular mechanisms governing these protomer interactions is critical for advancing understanding of the roles of class A GPCR in physiological and pathological processes, while also providing novel avenues for therapeutic development26,135. Bidirectional modulation of dimer assembly and ligand binding In contrast to classical dimeric class C GPCRs, class A GPCR dimers exhibit less stable interactions and display a relatively dynamic equilibrium between monomeric and dimeric patterns26. Thus, ligand stimulation can dynamically modulate the dimer formation, promoting the association or dissociation events (Fig. 3a). For example, the D2R antagonist haloperidol disrupts protomer interactions in the D2R-TAAR1 heterodimer66, while both D1R-D2R and D2R-SSTR5 heterodimers dissociate into monomers following the antidepressant treatment12,87. Moreover, the proportion of the 5-HT1AR-D2R heterodimer in the mouse cortex increases in response to atypical antipsychotics, including clozapine, olanzapine, aripiprazole, and lurasidone, but decreases upon D2R antagonist haloperidol treatment18. These findings highlight the ligand-dependent dynamic nature of class A GPCR dimers and suggest that small molecules designed to stabilize specific dimeric states could provide a powerful strategy for pharmacological modulation and therapeutic development.Fig. 3Dynamic and allosteric modulation of class A GPCR dimerization.a Ligand-dependent dynamic dimer formation process. b The impact of one protomer conformational change on the affinity of a specific ligand for the other protomer in the dimer. c Allosteric modulation of one protomer on the intrinsic signaling efficacy or potency of the other protomer, including positive crosstalk, negative crosstalk, cross-activation, and cross-inhibition. d Co-activation of both protomers in the dimer induced a novel transducer protein recruitment different from their primary coupling. e Co-activation of both protomers in the dimer induced biased signaling, and most dimerization-biased signaling is arrestin-biased signaling, subsequently inducing the dimer internalization. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. Dynamic and allosteric modulation of class A GPCR dimerization. a Ligand-dependent dynamic dimer formation process. b The impact of one protomer conformational change on the affinity of a specific ligand for the other protomer in the dimer. c Allosteric modulation of one protomer on the intrinsic signaling efficacy or potency of the other protomer, including positive crosstalk, negative crosstalk, cross-activation, and cross-inhibition. d Co-activation of both protomers in the dimer induced a novel transducer protein recruitment different from their primary coupling. e Co-activation of both protomers in the dimer induced biased signaling, and most dimerization-biased signaling is arrestin-biased signaling, subsequently inducing the dimer internalization. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. Ligands not only can influence dimer assembly and dissociation but also modulate the binding properties of individual protomers through allosteric interactions within the dimer. In such complexes, a ligand’s affinity may differ from its action on a monomer, depending on the conformational state of the partner protomer136 (Fig. 3b). For instance, in the D2R-OTR heterodimer, oxytocin (an OTR agonist) enhanced both agonist binding affinity and Gi/o signaling of D2R, which could be reversed by the OTR antagonist L-3688998388. In the 5-HT1AR-5-HT2AR heterodimer, TCB2-mediated 5-HT2AR activation significantly reduced the binding affinity of the 5-HT1AR agonist ipsapirone, which could be restored by the 5-HT2AR antagonist ketanserin17. Similar allosteric modulation of ligand binding has been observed in other class A GPCR dimers, including D1R-D2R14, D1R-D3R47, D2R-H3R58, D2R-A2AR74, D3R-A2AR76, 5-HT2AR-5-HT2CR110, 5-HT2BR-5-HT2CR110, and 5-HT2AR-D2R64. These observations highlight the substantial complexity introduced by protomer-protomer interactions and emphasize the critical role of allosteric modulation in shaping the pharmacological properties of class A GPCR dimers. Dimer-induced signaling reprogramming Receptor dimerization reprograms downstream signaling by introducing allosteric interactions between protomers that reshape signaling efficacy, transducer recruitment, and pathway bias137. These effects can be broadly grouped into: (1) modulation of intrinsic signaling output of individual protomers (Fig. 3c), (2) switched signaling, in which the dimer recruits noncanonical transducer proteins (Fig. 3d), and (3) biased signaling, characterized by the preferential engagement of specific transducers such as β-arrestins that regulate receptor trafficking and internalization (Fig. 3e). Dimerization can modulate the intrinsic signaling output of individual protomers, manifesting as positive crosstalk, negative crosstalk, cross-activation, or cross-inhibition (Fig. 3c). When both protomers are simultaneously activated by their respective selective agonists, the resulting dimeric signaling output may exhibit either amplification or suppression of downstream responses relative to monomeric signaling, corresponding to positive and negative crosstalk, respectively. Notably, most coactivated dimers display negative crosstalk in their allosteric modulation19,59,68,74,83,97,111,120, whereas positive crosstalk is comparatively rare56,61,66,90. The most well-documented and conclusive evidence for positive crosstalk among class A GPCR dimers is found in the D2R-OTR heterodimer, in which the intrinsic OTR agonist oxytocin significantly enhances dopamine-mediated Gi/o coupling, as demonstrated by GTPγS accumulation assays88. These in vitro observations are further supported by in vivo studies showing oxytocin-mediated facilitation of D2R signaling89,90. Cross-activation refers to ligand-independent signaling from one protomer triggered by activation of its dimeric partner, exemplified by the 5-HT2CR-MT2R heterodimer, where MT2R stimulation initiates 5-HT2CR-mediated Gq/11 signaling116,117. In contrast, cross-inhibition describes a phenomenon in which agonist-evoked signaling at one protomer is suppressed when the partner protomer is bound by its selective antagonist. This has been clearly demonstrated in the D1R-μOR heterodimer, where SCH23390-mediated D1R antagonism markedly reduces μOR agonist-induced signaling both in vitro and in vivo81. In addition to modulating intrinsic signaling, dimerization can also induce switched transducer recruitment, allowing GPCR dimers to engage signaling proteins that their monomeric counterparts do not typically couple to, a phenomenon known as switched signaling39 (Fig. 3d). The D1R-D2R heterodimer represents the best-characterized example of switched signaling among class A GPCR dimers. Whereas monomeric D1R and D2R primarily couple to Gs and Gi/o proteins, respectively, their co-activation within the dimer instead recruits Gq/11 and activates PLC, leading to increased calcium-calmodulin kinase IIα (CaMKII) signaling11,14. However, another study was unable to detect Gq/11 coupling to D1R-D2R heterodimer94. The authors point out that the evidence implicating Gq/11 signaling of D1R-D2R heterodimer is primarily based on indirect measurements, like calcium measurements or inositol triphosphate (IP3) production but not on the direct study of Gq/11 recruitment94. Another example of switched signaling occurs in the 5-HT2AR-CB1R heterodimer. Specifically, dimerization has been reported to cause a switch in the G protein coupling of 5-HT2AR from Gq/11 to Gi/o proteins45. This diversification of downstream pathways through switched mechanisms broadens the functional landscape of GPCR dimers and provides new opportunities for pharmacological intervention, including the potential to uncover novel therapeutic indications for existing drugs. Dimerization may also reshape downstream responses by introducing protomer- or signal-biased pathways138. Protomer-biased signaling, also known as asymmetric recruitment, occurs when a heterodimer preferentially engages one protomer’s signaling pathway over the other. Such asymmetric signaling has been extensively characterized in class C GPCRs, including metabotropic glutamate (mGlu) receptors and γ-aminobutyric acid B (GABAB) receptor139. Among class A dimers, 5-HT2CR exerts dominant functional control over 5-HT2AR and 5-HT2BR in their heterodimers, suppressing both binding and signaling of the partner protomers120. Thus, asymmetric G protein recruitment between protomers can also be interpreted in terms of negative or positive crosstalk as described previously. Signal-biased recruitment refers to the selective engagement of specific downstream effectors, most manifested as bias between G protein- and arrestin-mediated signaling pathways. Dimerization-induced arrestin-biased signaling represents a distinct mechanism driving heterodimer internalization: for example, simultaneous activation of both protomers in the D2R-CB1R heterodimer triggers robust β-arrestin-1 recruitment and receptor co-internalization78,79. Understanding the mechanisms underlying dimer-induced arrestin bias would inform strategies to minimize the adverse effects of classical GPCR ligands, including desensitization and tolerance140. Structural insights into the class A GPCR dimerization Despite extensive biochemical and biophysical evidence supporting the existence of both homo- and hetero-dimers among class A GPCRs, structural insights into these dimers remain exceedingly limited (Table 3). In contrast, structural studies of class C GPCRs, which function as obligate dimers and exhibit well-defined structural architectures, are relatively extensive. Representative examples include the heterodimeric structure of the GABAB1-GABAB2141, as well as the homodimeric structure of the calcium-sensing receptor (CaSR)142 and the mGlu2143. Characterized by large extracellular venus flytrap (VFT) domains, class C receptors form dimers through both extracellular and transmembrane interactions, and activation is mediated by transmembrane domain (TMD) rearrangements in which diverse inactive state interfaces uniformly converge to a TM6-TM6 interface upon transition to the active state144 (Fig. 4b). Another example of obligate dimerization is observed in the class D fungal receptor Ste2, which lacks a large extracellular domain (ECD) yet consistently forms its dimer interface through TM1-TM2 in both inactive and active states145 (Fig. 4d). In contrast to these structurally resolved dimeric systems, only a handful of class A GPCR dimer structures have been determined to date using crystallography or cryo-electron microscopy (cryo-EM), and all of them are homodimers. To advance the understanding of class A dimerization paradigms and facilitate the discovery of additional dimeric assemblies, we performed a comprehensive structural analysis of currently available structures of the class A GPCR dimers.Fig. 4Extracellular views of the interaction interfaces in structurally resolved class A, class C, and class D GPCR oligomers.a Extracellular view of class A dimers or oligomers structures. The alignment of dimer structures with similar interfaces reveals four distinct types of class A dimer interface: TM1-TM2, TM3-TM3, TM5-TM6, and TM1-TM7 (from the top to the bottom). b Extracellular view of G protein-free and G protein-coupled structures of class C dimers. The diversiform interfaces of class C dimer transform to the consistent TM6-TM6 interaction upon the engagement of the G protein. c Extracellular view of G protein-free and G protein-coupled structures of APJR and GPR3 dimers. The dimer interface remains unchanged before and after G protein coupling. d Extracellular view of inactive and active state structures of class D STE2 dimers. The dimer interface remains unchanged before and after G protein coupling.Table 3The structural features of class A GPCR dimersOligomerD/O#MethodInterfaceBuried Surface Area (Å2)*Signal ProteinAuxiliary ProteinResolution (Å)PDB codeCXCR4-CXCR4DX-RayTM5, TM6957.3T4 lysozyme3.13OE9CXCR4-CXCR4DX-RayTM3, TM4, ICL2, TM5, TM61094.3T4 lysozyme2.93OE0CXCR4-CXCR4DX-RayTM5, TM61187.4T4 lysozyme2.53ODUMOR-MORD/OX-RayTM1, TM2, H8588T4 lysozyme2.84DKLMOR-MORD/OX-RayTM5, TM61585.6T4 lysozyme2.84DKLβ1AR-β1ARD/OX-RayTM1, TM2, H8833.63.54GPOβ1AR-β1ARD/OX-RayTM4, TM5, ICL2450.43.54GPORhodopsin-RhodopsinDCryo-EMTM1, H8671.64.56OFJAPJR-APJRDCryo-EMTM3, ECL1269.9WT Gi1scFv16, BRIL3.577W0LAPJR-APJRDCryo-EMTM3, ECL1180.7WT Gi1scFv16, BRIL4.217W0NAPJR-APJRDCryo-EMTM3, ECL1208.6BRIL2.958XQJAPJR-APJRDCryo-EMTM3, ECL1200.8BRIL3.018Z74APJR-APJRDCryo-EMTM3, ECL1199.0BRIL3.258XQIAPJR-APJRDCryo-EMTM3, ECL1234.6βarr1-scFv30V2RC3.579KUXAPJR-APJRDCryo-EMTM3, ECL1215.4βarr1-scFv30V2RC3.499KUWCXCR4 trimerOCryo-EMTM1-TM71149.93.358U4SCXCR4 tetramerOCryo-EMTM1-TM7802.53.388U4TGPR3-GPR3DCryo-EMTM3, TM5, TM61017.5Nb35, aspartate racemase (PDB: 1IU9), BRIL3.669LYDGPR3-GPR3DCryo-EMTM3, TM5, TM61025.1DN GsNb35, BRIL3.069LYCGPR3-GPR3DCryo-EMTM3, TM5, TM6935.8PGS, BRIL3.109M88GPR3-GPR3DCryo-EMTM3, TM5, TM6927.7BRIL3.429M8PGPR3-GPR3DCryo-EMTM3, TM5, TM6957.9WT GsBRIL3.839M8V#D and O represent Dimer and Oligomer, respectively.*Buried surface area was calculated using PISA v1.52 (https://www.ebi.ac.uk/pdbe/pisa/). Extracellular views of the interaction interfaces in structurally resolved class A, class C, and class D GPCR oligomers. a Extracellular view of class A dimers or oligomers structures. The alignment of dimer structures with similar interfaces reveals four distinct types of class A dimer interface: TM1-TM2, TM3-TM3, TM5-TM6, and TM1-TM7 (from the top to the bottom). b Extracellular view of G protein-free and G protein-coupled structures of class C dimers. The diversiform interfaces of class C dimer transform to the consistent TM6-TM6 interaction upon the engagement of the G protein. c Extracellular view of G protein-free and G protein-coupled structures of APJR and GPR3 dimers. The dimer interface remains unchanged before and after G protein coupling. d Extracellular view of inactive and active state structures of class D STE2 dimers. The dimer interface remains unchanged before and after G protein coupling. Table 3The structural features of class A GPCR dimersOligomerD/O#MethodInterfaceBuried Surface Area (Å2)*Signal ProteinAuxiliary ProteinResolution (Å)PDB codeCXCR4-CXCR4DX-RayTM5, TM6957.3T4 lysozyme3.13OE9CXCR4-CXCR4DX-RayTM3, TM4, ICL2, TM5, TM61094.3T4 lysozyme2.93OE0CXCR4-CXCR4DX-RayTM5, TM61187.4T4 lysozyme2.53ODUMOR-MORD/OX-RayTM1, TM2, H8588T4 lysozyme2.84DKLMOR-MORD/OX-RayTM5, TM61585.6T4 lysozyme2.84DKLβ1AR-β1ARD/OX-RayTM1, TM2, H8833.63.54GPOβ1AR-β1ARD/OX-RayTM4, TM5, ICL2450.43.54GPORhodopsin-RhodopsinDCryo-EMTM1, H8671.64.56OFJAPJR-APJRDCryo-EMTM3, ECL1269.9WT Gi1scFv16, BRIL3.577W0LAPJR-APJRDCryo-EMTM3, ECL1180.7WT Gi1scFv16, BRIL4.217W0NAPJR-APJRDCryo-EMTM3, ECL1208.6BRIL2.958XQJAPJR-APJRDCryo-EMTM3, ECL1200.8BRIL3.018Z74APJR-APJRDCryo-EMTM3, ECL1199.0BRIL3.258XQIAPJR-APJRDCryo-EMTM3, ECL1234.6βarr1-scFv30V2RC3.579KUXAPJR-APJRDCryo-EMTM3, ECL1215.4βarr1-scFv30V2RC3.499KUWCXCR4 trimerOCryo-EMTM1-TM71149.93.358U4SCXCR4 tetramerOCryo-EMTM1-TM7802.53.388U4TGPR3-GPR3DCryo-EMTM3, TM5, TM61017.5Nb35, aspartate racemase (PDB: 1IU9), BRIL3.669LYDGPR3-GPR3DCryo-EMTM3, TM5, TM61025.1DN GsNb35, BRIL3.069LYCGPR3-GPR3DCryo-EMTM3, TM5, TM6935.8PGS, BRIL3.109M88GPR3-GPR3DCryo-EMTM3, TM5, TM6927.7BRIL3.429M8PGPR3-GPR3DCryo-EMTM3, TM5, TM6957.9WT GsBRIL3.839M8V#D and O represent Dimer and Oligomer, respectively.*Buried surface area was calculated using PISA v1.52 (https://www.ebi.ac.uk/pdbe/pisa/). The structural features of class A GPCR dimers #D and O represent Dimer and Oligomer, respectively. *Buried surface area was calculated using PISA v1.52 (https://www.ebi.ac.uk/pdbe/pisa/). Molecular architecture of class A GPCR homodimers Although only a limited number of class A GPCR dimer structures have been determined by crystallography or cryo-EM, these structures still reveal diverse modes of protomer association and provide important insights into how receptors organize and signal. Because crystallographic dimers might arise from packing forces rather than represent biologically relevant interfaces, we only focus on structures explicitly reported as functional symmetrical dimers in their original publications. Buried surface area (BSA) could help to evaluate the likelihood of physiological relevance, as biologically meaningful interfaces generally display larger BSAs, whereas packing-derived interfaces tend to show smaller values. In contrast to crystallography, cryo-EM can visualize the dimers in a more native environment without the constraints of crystal formation, enabling the capture of dynamic and physiologically relevant dimeric states while reducing concerns about packing artifacts146. To provide an overview of the structural architectures identified so far, we summarize representative assemblies determined by crystallography and cryo-EM, including three crystallographic dimers (CXCR4147, μOR148, and β1AR149), three cryo-EM dimers (rhodopsin150 and the recently resolved APJR151–153 and GPR3154–156 dimers), and one cryo-EM oligomer (CXCR4157) (Fig. 4). Among these assemblies, APJR and GPR3 will be discussed in detail in the following section. Across these structures, most assemblies adopt parallel, symmetric protomer organization, and the interfaces could be classified into four types: TM1–TM2, TM3–TM3, TM5–TM6, and TM1–TM7 (Fig. 4a and Table 3). These interface types provide a framework for comparing how different class A GPCRs engage in dimerization, but individual receptors can exhibit notable variations in interface composition and BSA. The CXCR4 structures highlight this variability, with the IT1t-bound dimer engaging mainly extracellular TM5–TM6 contacts, whereas the CVX15-bound structure forms a more extensive interface incorporating TM3, TM4, and ICL2 in addition to extracellular TM5–TM6 interactions, yielding BSA values of 957.3 Ų and 1094.3 Ų, respectively147 (Table 3). The μOR dimer crystallized with β-FNA similarly features two interface types, TM1–TM2–H8 and TM5–TM6, with BSAs of 588 Ų and 1585.6 Ų, respectively148 (Fig. 4a). The β1AR dimer adopts an inactive conformation stabilized by TM1–TM2–H8 and TM4–TM5–ICL2 interfaces, with BSA values of 833.6 Ų and 450.4 Ų, respectively149. The first cryo-EM dimer structure of a class A GPCR, obtained from the cross-linked rhodopsin in nanodiscs at 4.5 Å resolution150, reveals a TM1–H8 interface with a BSA of 671.6 Ų. Notably, higher-order CXCR4 assembly resolved by cryo-EM, unlike its crystallographic counterparts, utilizes a TM1–TM7 interface59, and the T4L fusion used in crystallization likely hindered trimer or tetramer formation157 (Fig. 4a). Activation insights into APJR and GPR3 dimers As the apelin receptor (APJR) and GPR3 are the only class A GPCR homodimers with both inactive- and active-state structures resolved, we focus on these two receptors to elucidate the mechanisms underlying receptor activation and transducer engagement in class A GPCR dimers. The first structurally characterized example is the APJR homodimer bound to either its endogenous peptide agonist elabela (ELA) or a small-molecule agonist, cmpd644, in complex with the Gi/o heterotrimer158. The dimeric interface of APJR is relatively small, primarily involving the tip of TM3 and ICL1, with the BSA values of only 180.7 Ų for the ELA-bound state and 269.9 Ų for the cmpd644-bound state (Table 3). Notably, only one protomer in this dimer couples to the Gi/o heterotrimer in the G-protein coupled state. As APJR dimerization is a ligand-independent constitutive process, the APJR structures of ligand-free (apo) and antagonistic antibody (JN241)-bound state in the absence of Gi/o proteins were determined151. Although the G protein is absent, the dimer still forms through TM3–TM3 interactions but adopts a more compact configuration (Fig. 4c). More recently, dimeric APJR associated with one or two βarr1 molecules has been resolved, revealing that full APJR activation requires both protomers to couple to βarr1152. The APJR-βarr1 complex at stoichiometries of 2:2 and 2:1 shares an overall similar conformation with a small dimerization interface comparable to that of the Gi/o-engaged complex152. The rearrangements of conserved GPCR activation motifs in the APJR dimer active state, such as the outward movement of TM6 and the downward displacement of W6.48, are largely consistent with activation features of class A GPCR monomers (Fig. 5).Fig. 5Key features of class A GPCR dimer activation revealed by APJR structures.a Side view of apo state (lightblue) and cmpd644-bound active states: Gi-coupled (APJR: palegreen, cmpd644: lightorange) and βarr1-coupled (APJR: paleyellow, cmpd644: violet) of APJR dimers. The TM6 outward shifts and important microswitches rearrangement involved in the APJR activation are highlighted, including b the toggle switch W2616.48 and P5.50I3.40F6.44 motif; c the sodium-binding pocket; d the N7.49P7.50xxY7.53 motif; and e the D3.49R3.50Y3.51 motif. Key features of class A GPCR dimer activation revealed by APJR structures. a Side view of apo state (lightblue) and cmpd644-bound active states: Gi-coupled (APJR: palegreen, cmpd644: lightorange) and βarr1-coupled (APJR: paleyellow, cmpd644: violet) of APJR dimers. The TM6 outward shifts and important microswitches rearrangement involved in the APJR activation are highlighted, including b the toggle switch W2616.48 and P5.50I3.40F6.44 motif; c the sodium-binding pocket; d the N7.49P7.50xxY7.53 motif; and e the D3.49R3.50Y3.51 motif. Along with APJR, GPR3 provides another example of a class A GPCR exhibiting both G protein-coupled and G protein-free dimeric states154,156. The dimeric interface of GPR3 is primarily mediated by TM5-TM6, resembling the dimeric arrangement observed in CXCR4 and μOR homodimers (Fig. 4a, c). This interaction interface remains unchanged between inactive and active conformations. Notably, the GPR3 dimer exhibits a substantially larger interface than APJR, with BSA values of 1017.5 Ų (G protein-free) and 1025.1 Ų (dominant-negative Gs (DNGs) heterotrimer-coupled), respectively (Table 3). Although a dimeric GPR3 structure coupled to two miniGs proteins has been reported155, the GPR3 dimer recruits only one DNGs or wild-type Gs heterotrimer. This is likely because two full-sized G-protein heterotrimers cannot bind at the same time due to steric hindrance, while miniGs is small enough to fit because its helical domain is truncated154–156. Effects of lipids on class A GPCRs dimerization As class A GPCR dimer interfaces are embedded within the phospholipid bilayer and predominantly mediated by TM helices, the local lipid environment can strongly influence receptor-receptor association. This principle is exemplified by the NTSR1, previously described as a “rolling dimer” in which multiple dimer conformations coexist and interconvert36. Molecular dynamics (MD) simulations showed that increasing the fatty-acid chain length of saturated lipids enhances hydrophobic mismatch with NTSR1, promoting excessive dimerization159. Lipid-dependent modulation is also evident for CXCR4, a receptor known to form dimers and higher-order oligomers. Early work demonstrated that depletion of membrane cholesterol (CLR) reduced CXCR4 dimerization160. More recent cryo-EM structures revealed that specific lipids at the interprotomer interface contribute to the assembly of CXCR4 trimers and tetramers, with three phosphatidic acids and three cholesterol molecules observed in the trimeric central cavity, and four phosphatidic acids along with eight cholesterol molecules in the tetrameric cavity157 (Fig. 6a). The lipid number along the central axis correlates with protomer packing: the trimer containing three lipids exhibits a BSA value of 1149.9 Ų, whereas the tetramer with four lipids shows a reduced BSA of 802.5 Ų, consistent with looser interprotomer contacts. Recent structural studies further extend this concept to APJR, where ligand-free (apo) and G protein-coupled dimers revealed an equilibrium between monomeric and dimeric states151,158. The cholesterol molecules are only present at the ligand-free dimer interface, but absent from the agonist-bound interface. Agonist binding followed by G-protein engagement shifts the equilibrium toward the monomer, and cholesterol likely contributes to stabilizing the apo dimer151 (Fig. 6b). In addition, a recent preprint article also highlights the critical role of cholesterol clusters in stabilizing the APJR dimers in different states153.Fig. 6Lipid-mediated assembly and stabilization of class A GPCR dimers.a Side and extracellular views of CXCR4 trimer (marine, PDB 8U4S) and tetramer (density, PDB 8U4T). The phosphatidic acids (green) and cholesterol molecules (yellow) are highlighted. b Side view of ligand-free (paleblue, PDB 8XQJ) and G protein-coupled APJR dimers (palegreen, PDB 7W0L). The cholesterol molecules (yellow) between the protomers of the ligand-free APJR dimer are highlighted. Lipid-mediated assembly and stabilization of class A GPCR dimers. a Side and extracellular views of CXCR4 trimer (marine, PDB 8U4S) and tetramer (density, PDB 8U4T). The phosphatidic acids (green) and cholesterol molecules (yellow) are highlighted. b Side view of ligand-free (paleblue, PDB 8XQJ) and G protein-coupled APJR dimers (palegreen, PDB 7W0L). The cholesterol molecules (yellow) between the protomers of the ligand-free APJR dimer are highlighted. Key determinants of dimer formation in class A GPCR TM-mediated interfaces are the predominant mode of class A GPCR dimerization or oligomerization. CXCR4 exemplifies how subtle TM differences tune quaternary organization: three TM6 residues (K239, V242, L246) are essential for higher-order oligomerization but dispensable for dimer formation, indicating that discrete TM elements can selectively regulate oligomer vs dimer states157. The APJR homodimer is built on an unusually small contact surface dominated by hydrophobic and π−π interactions from a continuous FGTFF motif (F973.52, G983.21, T993.22, F1003.23, and F1013.24), with F1013.24 acting as a “dimer-switch” whose absence weakens the dimerization151,158. By contrast, the GPR3 dimer is stabilized by an extended interface spanning positions 5.37–5.67 with hydrophobic, hydrogen-bonding, and polar contacts. Notably, Y2135.58 adopts distinct conformations between protomers. In the G-protein-free protomer, it engages R1343.50 (DRY motif) and Y2977.53 (NPxxY motif) to stabilize the TM3–TM5–TM7 interaction, which may block G protein coupling. Combined with the bending of ICL3, this structural arrangement underlies an autoinhibited protomer state156. Alongside TM-mediated interfaces, class A GPCRs can also form highly stable non-canonical assemblies via electrostatic mechanisms. In particular, arginine–phosphate salt bridges, where clusters of adjacent arginines on one protomer engage acidic residues (glutamate, aspartate) or phosphorylated sites on the partner, provide exceptionally strong electrostatic attraction and have been proposed as a general mechanism for stabilizing non-covalent complexes161,162. Such arginine-phosphate interactions have been implicated in several dopamine-centered heterodimers (D2R-A2R, D1R-D2R, and D2R-D5R) and validated using FRET with mutants163–165. Unlike the common TM-mediated dimer interfaces, these non-covalent interactions occur primarily between the C-terminal tail and ICL3 of the protomers, representing a distinct mode of stabilization161–165. However, high-resolution structural data for these heterodimers are lacking, so these arginine-phosphate interactions were inferred from biochemical and biophysical experiments rather than directly visualized. Dimer-targeted drug development Class A GPCRs form functional dimers under physiological conditions and contribute directly to disease-related signaling, highlighting new opportunities for developing therapeutics that exploit dimer-specific properties. Firstly, because of the unique signaling outcomes induced by the dimerization distinct from monomers, modulating the monomer-dimer equilibrium itself represents a rational drug development strategy (Fig. 7a). Several class A GPCRs exhibit ligand-dependent association, including D1R-D2R12, D2R-SSTR586,87, D2R-TARR166, and 5-HT1AR-D2R18 heterodimers, and these assemblies often play different roles across disease states. For example, the proportion of D1R-D2R dimers increases in depression12 but is impaired in schizophrenia13. Once the pathological relevance of a specific dimer is established, ligands that promote or disrupt receptor association could be used to rebalance signaling outputs (Fig. 7a). Another therapeutic strategy arises from inter-protomer allosteric modulation, where ligand binding to one protomer alters the partner protomer’s signaling or ligand affinity, analogous to classical allosteric modulation but driven by the protomer-protomer interaction137,166 (Fig. 7b). A well-established example occurs in the D2R-A2AR complex, where A2AR antagonists enhance D2R dopamine affinity, providing a mechanistic basis for A2AR antagonist monotherapy in early Parkinson’s disease167.Fig. 7Dimer-specific strategies for GPCR-targeted drug development.a Monomer-dimer dynamic equilibrium exhibits distinct tendencies under different pathological conditions, including insufficient dimerization or excessive dimerization. b Allosteric modulation between protomers on their intrinsic signaling used for drug development, like (i) positive/negative crosstalk and (ii) cross activation/inhibition; (iii) designed ligand indirectly regulates downstream coupling by affecting the ligand binding affinity. c Bivalent ligand for enhancing dimer stability and providing novel signaling, like (iv) switched signaling and (v) arrestin-biased signaling. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. Dimer-specific strategies for GPCR-targeted drug development. a Monomer-dimer dynamic equilibrium exhibits distinct tendencies under different pathological conditions, including insufficient dimerization or excessive dimerization. b Allosteric modulation between protomers on their intrinsic signaling used for drug development, like (i) positive/negative crosstalk and (ii) cross activation/inhibition; (iii) designed ligand indirectly regulates downstream coupling by affecting the ligand binding affinity. c Bivalent ligand for enhancing dimer stability and providing novel signaling, like (iv) switched signaling and (v) arrestin-biased signaling. Created in BioRender. Wang, Z. (2026) https://BioRender.com/ko6t9gu. The distinct ligand-binding landscape created by GPCR dimers has also motivated the development of dual-targeting molecules, among which bivalent ligands are the most thoroughly explored168,169. These compounds consist of two pharmacophores covalently linked by a chemical spacer and are designed to simultaneously bind both protomers within a functional dimer169,170 (Fig. 7c). Bivalent ligands can achieve higher affinity and improved selectivity relative to monovalent ligands171. Their design relies on selecting appropriate pharmacophores, often clinically approved drugs or highly selective ligands, and optimizing the spacer based on inter-protomer distances so that each pharmacophore can reach its binding pocket105,171. For instance, rationally designed bivalent ligands targeting D2R/D3R-NTSR1 heterodimers can stabilize receptor association and drive β-arrestin-mediated D2R/D3R internalization through NTSR1 activation85,105. Apart from rational design, large-scale compound screening can identify dimer-selective ligands with unique signaling profiles137. High-throughput screening (HTS) remains an effective starting point, particularly when using functional assays in cells co-expressing GPCR pairs. For instance, HTS of a small-molecule library led to the discovery of CYM51010, a selective activator of the μOR-δOR heterodimer that lacks activity at either receptor alone172. This compound provides a structural scaffold for developing heterodimer-biased opioids that may retain therapeutic efficacy while avoiding adverse effects associated with classical opioids172. As mechanistic knowledge of GPCR dimer interactions continues to expand, integrating structure-based design, sensor technologies, and compound libraries such as DNA-encoded libraries with conventional HTS is expected to accelerate dimer-focused drug discovery173–175. Discussion and conclusion Increasing evidence indicates that class A GPCR dimerization plays a crucial role in neuropsychiatric biology, shaping disease-specific signaling pathways across conditions such as depression, schizophrenia, addiction, anxiety disorders, and neurodegenerative diseases8,9,22,137. It is important to note that the majority of studies to date have focused on alterations in the downstream signaling of these dimers. Consequently, links to disease are frequently inferred from correlative signaling changes rather than demonstrated through direct validation in relevant disease models. As such, these exciting findings require cautious interpretation and underscore the importance of future validation in in vivo disease models. Structural insights are essential for understanding how these dimers assemble, signal, and transit between states. However, the dynamic nature of class A GPCRs limits the determination of high-resolution structures, particularly for heterodimers, which remain structurally uncharacterized. Although capturing physiologically relevant dimers remains challenging, advances such as NanoBiT tethering, bivalent ligand stabilization, and improved cryo-EM methodologies are beginning to overcome these obstacles37,168,176. Most recently, several preprint studies have provided additional structural evidence to reveal the dynamic monomer-dimer equilibrium of class A GPCR dimers, which can be modulated by ligand binding, membrane components, or transducer coupling153,177,178. Specifically, an optimized derivative of a β-arrestin-biased negative allosteric modulator of β2AR was shown to act as a molecular glue that stabilizes the β2AR dimeric conformation177; a dimeric CXCR7 structure revealed that a native phospholipid can stitch the two protomers together178; and G-protein coupling was found to drive the transition of APJR from a dimeric to a monomeric state153. Elucidating the structure-function relationship of class A GPCR heterodimers remains challenging due to the absence of high-resolution experimental structures. Current mechanistic understanding therefore largely derives from well-characterized homodimers. Notably, APJR151,152,158 and GPR3155,156 stand out as the only currently available class A homodimers with both inactive- and active-state structures resolved. Analysis of these structures converges on a central theme: asymmetric activation. In both dimers, steric constraints appear to hinder the simultaneous recruitment of two signaling proteins, favoring engagement by only one protomer, as observed in class C GPCRs. This asymmetry leads to functional outcomes described as partial activation or negative crosstalk, resulting in attenuated signaling compared with monomers or symmetrically active dimers152. Although direct structural evidence is lacking, the steric constraints observed in homodimers may conceptually extend to heterodimers, offering a possible structural explanation for the prevalence of negative allosteric modulation reported in functional studies of coactivated heterodimers. Together, these findings expand the traditional monomer-centric view of the class A GPCR function and reveal an additional layer of signaling complexity with direct relevance to disease mechanisms and precision therapeutics. As the field moves forward, expanding high-resolution structural datasets, deepening our understanding of dimer-specific signaling mechanisms, and developing robust methods to validate physiologically relevant dimers in native environments will be crucial. These advances will not only refine our mechanistic understanding of class A GPCR pharmacology but also lay the foundation for dimer-informed drug discovery, enabling the development of more selective, effective, and clinically meaningful therapeutics for neuropsychiatric disorders.